Observes telitacicept with tofacitinib in refractory rheumatoid arthritis
Observes telitacicept combined with tofacitinib in adults with refractory rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis
Key facts
- Where
- Hangzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT06979271, who can take part
Where in China
- Zhejiang Provincial People's HospitalHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhejiang Provincial People's Hospital
- Trial code
- NCT06979271
- Record updated
- 18 May 2025
- Original description
The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with tofacitinib in the treatment of D2TRA patientsRead full original descriptionShow less
Clinical Efficacy and Safety of Real-world Patients With Refractory Rheumatoid Arthritis (D2TRA) Receiving Telitacicept in Combination With Tofacitinib
The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with tofacitinib in the treatment of D2TRA patients
Inclusion: Age 18-85 years; Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria; The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease-improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients; Voluntarily provided written informed consent -.
Exclusion: Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs); Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis); History of allergy/hypersensitivity to the study medications (Telitacicept or Tofacitinib); Active tuberculosis or active infectious diseases requiring systemic treatment; Failure to complete the prescribed Telitacicept + Tofacitinib regimen due to: Non-adherence or Severe adverse reactions; Other conditions contraindicating participation per investigator judgment -; Pregnancy, lactation, or refusal to use contraception during the study.